Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.33 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in tuft cells | 0.75 |
| chemistry Open Targets | compounds already reach it: danuglipron, exenatide, cotadutide +14 | 0.90 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 64 Parkinson's papers of 3,214 | 0.45 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1035
Sealed predictions
- GLP1R in dopamine neurons, braak-0.23 (p 0.554) → -0.30 (p 0.436)receipt 1041
Swarm cases
receipt 1041: GLP1R in dopamine neurons, braak
- power
- full sample -0.29 (p 0.239, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.239, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.080, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.239, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GLP1R in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts